Since the invasion of Ukraine, hundreds of companies have announced a pause or withdrawal of businesses in Russia. Drugmakers Eli Lilly, Novartis and AbbVie are …

Despite classwide safety worries in the U.S., AbbVie is making strides in its quest to build immunology up-and-comer Rinvoq. AbbVie sent off applications to U.S. and …

On the day of closing arguments in a high-profile New York opioid trial, AbbVie has inked a $200 million settlement to put the case to …

The second regulatory shoe has finally dropped for AbbVie, Pfizer and Eli Lilly amid the safety review of JAK inhibitors for inflammatory diseases. But confirmed …

AbbVie’s blockbuster hopeful Rinvoq notched a win in a tricky-to-treat group of Crohn’s disease patients, potentially adding another arrow to the company’s post-Humira quiver. The …

Alvotech, the biosim specialist locked in a legal battle over AbbVie’s sales Goliath Humira, is revving up for its debut on the Nasdaq. The Icelandic …

Over the years, the Institute for Clinical and Economic Review (ICER) has emerged as a champion in the fight against high U.S. drug costs. In …

Since scoring an FDA approval earlier this year to both treat and prevent migraine, Biohaven’s Nurtec ODT has jumped out ahead of Big Pharma rival …

Revance Therapeutics has traveled a long road to a potential FDA approval for its Botox competitor, including COVID delays that pushed back plant inspections. Now, …

As officials in Washington weigh contentious drug-pricing measures, there’s even more evidence that pharma companies are worried about potential reform. In an open letter to …